WO1994002495A1 - Esterification process - Google Patents
Esterification process Download PDFInfo
- Publication number
- WO1994002495A1 WO1994002495A1 PCT/GB1993/001545 GB9301545W WO9402495A1 WO 1994002495 A1 WO1994002495 A1 WO 1994002495A1 GB 9301545 W GB9301545 W GB 9301545W WO 9402495 A1 WO9402495 A1 WO 9402495A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxyacid
- amine
- mixture
- water
- trehalose
- Prior art date
Links
- 238000005886 esterification reaction Methods 0.000 title claims abstract description 18
- 230000032050 esterification Effects 0.000 title claims abstract description 13
- 238000000034 method Methods 0.000 title claims description 67
- 230000008569 process Effects 0.000 title claims description 36
- 150000001412 amines Chemical class 0.000 claims abstract description 31
- 229910019142 PO4 Inorganic materials 0.000 claims abstract description 27
- 150000001875 compounds Chemical class 0.000 claims abstract description 26
- 150000002148 esters Chemical class 0.000 claims abstract description 25
- 239000010452 phosphate Substances 0.000 claims abstract description 15
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims abstract description 14
- 150000001450 anions Chemical class 0.000 claims abstract description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 28
- 239000000203 mixture Substances 0.000 claims description 22
- 150000003839 salts Chemical class 0.000 claims description 16
- 229910052757 nitrogen Inorganic materials 0.000 claims description 15
- 239000000243 solution Substances 0.000 claims description 15
- 125000005341 metaphosphate group Chemical group 0.000 claims description 13
- 239000011541 reaction mixture Substances 0.000 claims description 13
- 235000000346 sugar Nutrition 0.000 claims description 12
- 229960001760 dimethyl sulfoxide Drugs 0.000 claims description 11
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 10
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 229910052760 oxygen Inorganic materials 0.000 claims description 8
- 239000001301 oxygen Substances 0.000 claims description 8
- 229930006000 Sucrose Natural products 0.000 claims description 7
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 7
- 239000005720 sucrose Substances 0.000 claims description 7
- 239000003960 organic solvent Substances 0.000 claims description 6
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims description 5
- 239000005864 Sulphur Substances 0.000 claims description 5
- 125000005842 heteroatom Chemical group 0.000 claims description 5
- 239000002904 solvent Substances 0.000 claims description 5
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical group [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 claims description 4
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical group [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000002253 acid Substances 0.000 claims description 4
- 150000001413 amino acids Chemical class 0.000 claims description 4
- 239000007864 aqueous solution Substances 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 230000008020 evaporation Effects 0.000 claims description 4
- 238000010438 heat treatment Methods 0.000 claims description 4
- 150000002829 nitrogen Chemical group 0.000 claims description 4
- 239000001205 polyphosphate Substances 0.000 claims description 4
- 235000011176 polyphosphates Nutrition 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- 239000001226 triphosphate Substances 0.000 claims description 4
- 102000003886 Glycoproteins Human genes 0.000 claims description 3
- 108090000288 Glycoproteins Proteins 0.000 claims description 3
- 229920000388 Polyphosphate Polymers 0.000 claims description 3
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 3
- 229910052796 boron Inorganic materials 0.000 claims description 3
- 150000003999 cyclitols Chemical class 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 239000001257 hydrogen Chemical group 0.000 claims description 3
- 229920001223 polyethylene glycol Polymers 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 108090000623 proteins and genes Proteins 0.000 claims description 3
- 102000004169 proteins and genes Human genes 0.000 claims description 3
- 229910052710 silicon Chemical group 0.000 claims description 3
- 239000010703 silicon Chemical group 0.000 claims description 3
- 239000008107 starch Substances 0.000 claims description 3
- 150000005846 sugar alcohols Chemical class 0.000 claims description 3
- RYYWUUFWQRZTIU-UHFFFAOYSA-K thiophosphate Chemical compound [O-]P([O-])([O-])=S RYYWUUFWQRZTIU-UHFFFAOYSA-K 0.000 claims description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 claims description 2
- 102000002068 Glycopeptides Human genes 0.000 claims description 2
- 108010015899 Glycopeptides Proteins 0.000 claims description 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical group [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 claims description 2
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 claims description 2
- 239000004473 Threonine Substances 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- TVZISJTYELEYPI-UHFFFAOYSA-N hypodiphosphoric acid Chemical compound OP(O)(=O)P(O)(O)=O TVZISJTYELEYPI-UHFFFAOYSA-N 0.000 claims description 2
- MPNNOLHYOHFJKL-UHFFFAOYSA-K peroxyphosphate Chemical compound [O-]OP([O-])([O-])=O MPNNOLHYOHFJKL-UHFFFAOYSA-K 0.000 claims description 2
- ACVYVLVWPXVTIT-UHFFFAOYSA-M phosphinate Chemical compound [O-][PH2]=O ACVYVLVWPXVTIT-UHFFFAOYSA-M 0.000 claims description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-M phosphonate Chemical compound [O-]P(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-M 0.000 claims description 2
- 235000011178 triphosphate Nutrition 0.000 claims description 2
- UNXRWKVEANCORM-UHFFFAOYSA-N triphosphoric acid Chemical compound OP(O)(=O)OP(O)(=O)OP(O)(O)=O UNXRWKVEANCORM-UHFFFAOYSA-N 0.000 claims description 2
- DQJCDTNMLBYVAY-ZXXIYAEKSA-N (2S,5R,10R,13R)-16-{[(2R,3S,4R,5R)-3-{[(2S,3R,4R,5S,6R)-3-acetamido-4,5-dihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy}-5-(ethylamino)-6-hydroxy-2-(hydroxymethyl)oxan-4-yl]oxy}-5-(4-aminobutyl)-10-carbamoyl-2,13-dimethyl-4,7,12,15-tetraoxo-3,6,11,14-tetraazaheptadecan-1-oic acid Chemical compound NCCCC[C@H](C(=O)N[C@@H](C)C(O)=O)NC(=O)CC[C@H](C(N)=O)NC(=O)[C@@H](C)NC(=O)C(C)O[C@@H]1[C@@H](NCC)C(O)O[C@H](CO)[C@H]1O[C@H]1[C@H](NC(C)=O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DQJCDTNMLBYVAY-ZXXIYAEKSA-N 0.000 claims 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 claims 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical group [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 claims 1
- BHEPBYXIRTUNPN-UHFFFAOYSA-N hydridophosphorus(.) (triplet) Chemical group [PH] BHEPBYXIRTUNPN-UHFFFAOYSA-N 0.000 claims 1
- 150000004760 silicates Chemical class 0.000 claims 1
- 238000006243 chemical reaction Methods 0.000 abstract description 28
- 150000002894 organic compounds Chemical class 0.000 abstract description 5
- 230000008901 benefit Effects 0.000 abstract description 3
- 150000002772 monosaccharides Chemical class 0.000 abstract description 3
- 150000002482 oligosaccharides Polymers 0.000 abstract description 2
- 238000011938 amidation process Methods 0.000 abstract 1
- 239000000047 product Substances 0.000 description 16
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 15
- 235000021317 phosphate Nutrition 0.000 description 15
- -1 phosphate esters Chemical class 0.000 description 14
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 10
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 10
- 230000015572 biosynthetic process Effects 0.000 description 10
- 229910052698 phosphorus Inorganic materials 0.000 description 10
- 229940074410 trehalose Drugs 0.000 description 10
- 238000003786 synthesis reaction Methods 0.000 description 9
- 238000000425 proton nuclear magnetic resonance spectrum Methods 0.000 description 8
- 150000003014 phosphoric acid esters Chemical class 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 5
- 239000011574 phosphorus Substances 0.000 description 5
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 4
- 235000014633 carbohydrates Nutrition 0.000 description 4
- 150000001768 cations Chemical class 0.000 description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 4
- 238000004255 ion exchange chromatography Methods 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 239000000178 monomer Substances 0.000 description 4
- 150000008163 sugars Chemical class 0.000 description 4
- 229940074409 trehalose dihydrate Drugs 0.000 description 4
- MOMKYJPSVWEWPM-UHFFFAOYSA-N 4-(chloromethyl)-2-(4-methylphenyl)-1,3-thiazole Chemical compound C1=CC(C)=CC=C1C1=NC(CCl)=CS1 MOMKYJPSVWEWPM-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 238000005342 ion exchange Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 235000019983 sodium metaphosphate Nutrition 0.000 description 3
- 239000007858 starting material Substances 0.000 description 3
- HNSDLXPSAYFUHK-UHFFFAOYSA-N 1,4-bis(2-ethylhexyl) sulfosuccinate Chemical compound CCCCC(CC)COC(=O)CC(S(O)(=O)=O)C(=O)OCC(CC)CCCC HNSDLXPSAYFUHK-UHFFFAOYSA-N 0.000 description 2
- UEZVMMHDMIWARA-UHFFFAOYSA-N Metaphosphoric acid Chemical compound OP(=O)=O UEZVMMHDMIWARA-UHFFFAOYSA-N 0.000 description 2
- 230000002378 acidificating effect Effects 0.000 description 2
- 150000007513 acids Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 150000001735 carboxylic acids Chemical class 0.000 description 2
- 125000004122 cyclic group Chemical group 0.000 description 2
- 239000001177 diphosphate Substances 0.000 description 2
- XPPKVPWEQAFLFU-UHFFFAOYSA-J diphosphate(4-) Chemical compound [O-]P([O-])(=O)OP([O-])([O-])=O XPPKVPWEQAFLFU-UHFFFAOYSA-J 0.000 description 2
- 235000011180 diphosphates Nutrition 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 125000000524 functional group Chemical group 0.000 description 2
- 150000004676 glycans Chemical class 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 150000002500 ions Chemical class 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 229940127557 pharmaceutical product Drugs 0.000 description 2
- 239000002798 polar solvent Substances 0.000 description 2
- 229920001282 polysaccharide Polymers 0.000 description 2
- 239000005017 polysaccharide Substances 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 239000012064 sodium phosphate buffer Substances 0.000 description 2
- 159000000000 sodium salts Chemical class 0.000 description 2
- 239000007787 solid Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- LABSPYBHMPDTEL-JGZVXCDNSA-N trehalose-6-phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@@H]1O[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](COP(O)(O)=O)O1 LABSPYBHMPDTEL-JGZVXCDNSA-N 0.000 description 2
- 239000013638 trimer Substances 0.000 description 2
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 1
- 238000004679 31P NMR spectroscopy Methods 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical group CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- QGZKDVFQNNGYKY-UHFFFAOYSA-O Ammonium Chemical compound [NH4+] QGZKDVFQNNGYKY-UHFFFAOYSA-O 0.000 description 1
- USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 1
- 239000005695 Ammonium acetate Substances 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 201000009906 Meningitis Diseases 0.000 description 1
- 238000005481 NMR spectroscopy Methods 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 108010008038 Synthetic Vaccines Proteins 0.000 description 1
- RYYWUUFWQRZTIU-UHFFFAOYSA-N Thiophosphoric acid Chemical class OP(O)(S)=O RYYWUUFWQRZTIU-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- 150000001342 alkaline earth metals Chemical class 0.000 description 1
- 125000000217 alkyl group Chemical group 0.000 description 1
- AWUCVROLDVIAJX-UHFFFAOYSA-N alpha-glycerophosphate Natural products OCC(O)COP(O)(O)=O AWUCVROLDVIAJX-UHFFFAOYSA-N 0.000 description 1
- 229940059260 amidate Drugs 0.000 description 1
- 229940043376 ammonium acetate Drugs 0.000 description 1
- 235000019257 ammonium acetate Nutrition 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 150000008064 anhydrides Chemical class 0.000 description 1
- 239000003125 aqueous solvent Substances 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 125000004429 atom Chemical group 0.000 description 1
- 230000001580 bacterial effect Effects 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- UREBDLICKHMUKA-DVTGEIKXSA-N betamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-DVTGEIKXSA-N 0.000 description 1
- 229960002537 betamethasone Drugs 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000006696 biosynthetic metabolic pathway Effects 0.000 description 1
- 229910052792 caesium Inorganic materials 0.000 description 1
- TVFDJXOCXUVLDH-UHFFFAOYSA-N caesium atom Chemical compound [Cs] TVFDJXOCXUVLDH-UHFFFAOYSA-N 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 230000003197 catalytic effect Effects 0.000 description 1
- 230000001413 cellular effect Effects 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 238000013375 chromatographic separation Methods 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000008367 deionised water Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000010511 deprotection reaction Methods 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000005265 energy consumption Methods 0.000 description 1
- NPUKDXXFDDZOKR-LLVKDONJSA-N etomidate Chemical compound CCOC(=O)C1=CN=CN1[C@H](C)C1=CC=CC=C1 NPUKDXXFDDZOKR-LLVKDONJSA-N 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 125000005843 halogen group Chemical group 0.000 description 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 1
- 150000002484 inorganic compounds Chemical class 0.000 description 1
- 229910010272 inorganic material Inorganic materials 0.000 description 1
- 229960000367 inositol Drugs 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229910052746 lanthanum Inorganic materials 0.000 description 1
- FZLIPJUXYLNCLC-UHFFFAOYSA-N lanthanum atom Chemical compound [La] FZLIPJUXYLNCLC-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 229940100434 menadiol Drugs 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 125000004433 nitrogen atom Chemical group N* 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000004437 phosphorous atom Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 238000000053 physical method Methods 0.000 description 1
- 229920000137 polyphosphoric acid Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000004064 recycling Methods 0.000 description 1
- 239000011347 resin Substances 0.000 description 1
- 229920005989 resin Polymers 0.000 description 1
- 239000012266 salt solution Substances 0.000 description 1
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 description 1
- 238000007086 side reaction Methods 0.000 description 1
- AWUCVROLDVIAJX-GSVOUGTGSA-N sn-glycerol 3-phosphate Chemical compound OC[C@@H](O)COP(O)(O)=O AWUCVROLDVIAJX-GSVOUGTGSA-N 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 229910000162 sodium phosphate Inorganic materials 0.000 description 1
- 235000011008 sodium phosphates Nutrition 0.000 description 1
- 125000001424 substituent group Chemical group 0.000 description 1
- 229940126577 synthetic vaccine Drugs 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- QIWDGSYHBCMXSI-UHFFFAOYSA-J tetrasodium;(2-methyl-4-phosphonatooxynaphthalen-1-yl) phosphate;hexahydrate Chemical compound O.O.O.O.O.O.[Na+].[Na+].[Na+].[Na+].C1=CC=CC2=C(OP([O-])([O-])=O)C(C)=CC(OP([O-])([O-])=O)=C21 QIWDGSYHBCMXSI-UHFFFAOYSA-J 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- RYFMWSXOAZQYPI-UHFFFAOYSA-K trisodium phosphate Chemical compound [Na+].[Na+].[Na+].[O-]P([O-])([O-])=O RYFMWSXOAZQYPI-UHFFFAOYSA-K 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H11/00—Compounds containing saccharide radicals esterified by inorganic acids; Metal salts thereof
- C07H11/04—Phosphates; Phosphites; Polyphosphates
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/06—Phosphorus compounds without P—C bonds
- C07F9/08—Esters of oxyacids of phosphorus
- C07F9/09—Esters of phosphoric acids
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/582—Recycling of unreacted starting or intermediate materials
Definitions
- the present: invention relates to a process for the esterification of hydroxylated compounds.
- Esters particularly phosphate esters, are widespread in nature and occupy a central role in biochemical processes.
- carbohydrate phosphates which are used extensively for studying biosynthetic pathways, and inositol phosphates which act as secondary cellular messengers.
- these compounds are often present at low concentration and are usually difficult to isolate in pure form, it is often necessary to synthesise them chemically.
- ester functionalities include betamethasone, which is used in the treatment of asthma, and menadiol, which is used for haemorrhage control. Both of these compounds are orthophosphates.
- Phosphate esters are structural features of several bacterial polysaccharides which are used in vaccines to protect against diseases such as pneumonia and meningitis; synthetic antigens with this type of structure have, in recent years, been prepared with a view to using them as synthetic vaccines. It is therefore clear that the introduction of the ester functional group is necessary for the preparation of a number of pharmaceutical products. Another area in which esters have proved to be useful is in detailed biochemical studies, including studying the effects of structural modifications on the biological activity of various compounds.
- Such studies include pharmacological testing of new drugs and therapeutic agents and also investigations into the mechanism of diseases including cancer. In studies such as these, it is often particularly useful to use radioactive esters into which a radioactive isotope of one of the atoms has been incorporated.
- esters It is often impossible to obtain the required ester compounds by any other method than chemical synthesis but, in fact, the chemical synthesis of esters has, in the past, proved to be extremely difficult.
- Direct methods for the synthesis of esters are available and an example of such a method is the esterification of a hydroxylated compound (HC) using phosphoric acid or polyphosphoric acid (MacDonald, The Carbohydrates, 1A, 254 (1972) W. Pigman and D. Horton (Eds). Academic Press, New York).
- HCs hydroxylated compound
- MacDonald The Carbohydrates, 1A, 254 (1972) W. Pigman and D. Horton (Eds). Academic Press, New York.
- the utility of this method is limited because many HCs are sensitive to the reaction conditions which are, of course, strongly acidic and often the products undergo further reaction to form modified compounds such as cyclic esters or anhydrides. This route cannot therefore be used for most compounds.
- the present invention is based on the discovery that ester formation can be promoted remarkably easily in solutions containing a hydroxylated compound and an oxyacid salt.
- a process for the esterification of a hydroxylated compound (HC) other than a starch, or the amidation of an organic amine characterised in that the process comprises reacting the HC or amine with an oxyacid, oxyacid anion or a mixture thereof wherein the oxyacid or its anion is capable of accepting a lone pair of electrons from the oxygen of the HC or nitrogen of the amine.
- oxygen includes within its scope hetero-oxyacids in which one or more of the oxygen atoms have been replaced by a hetero atom, in particular one such as nitrogen, sulphur or a halogen atom.
- hetero-oxyacids include thiophosphates, halophosphates and phosphonitriles.
- hydroxylated compound refers to any compound containing a hydroxyl group or an alkoxy or phenoxy anion. Preferred hydroxylated compounds are hydroxylated organic compounds although inorganic compounds, for example oxyacids may be used.
- hydroxylated organic compounds include sugars, proteins, glycoproteins, peptides, glycopeptides and glycoconjugates and other molecules having sugar functionality, amino acids, alditols, cyclitols, phosphate esters and carboxylic acids.
- the conditions of the process of the present invention are quite surprisingly mild and one particular advantage of this is that, because of the mild pH conditions, it is not necessary to protect (and subsequently to deprotect) other functional groups of the HC. This means that the overall number of steps in the process is reduced and that therefore the overall yield of the final product is increased, thus increasing the cost-effectiveness of the esterification process. Furthermore, the mild reaction conditions also ensure that the reaction is suitable for nearly any starting material and that there is little likelihood of products undergoing unwanted further reaction.
- the oxyacid may be an oxyacid of an element M, which is capable of forming trimeric oxyacids of the structure:
- M is an electron accepting element
- X is oxygen or a hetero-atom such as sulphur or a substituted nitrogen atom
- Y is oxygen, hydrogen or a hetero atom such as sulphur or a substituted nitrogen atom
- n is 0 or 1 and m is 0 to 2, depending on the valency of M.
- elements M which are capable of forming trimeric oxyacids include phosphorus, boron and silicon.
- the nitrogen atom will be substituted by hydrogen or an alkyl group.
- Phosphorus is capable of forming the metaphosphate oxyacid. Because of electron deficiency at the phosphorus atom, the ion tends to polymerise and may form the following trimer:
- boron forms an oxyacid having the following structure:
- metaphosphoric acid One suggestion for the reaction mechanism for esterification using a metaphosphate is as follows:
- This reaction mechanism indicates that it is the metaphosphate monomer rather than the trimer which is the reactive species.
- the usefulness of the invention is net dependent on the accuracy or otherwise of this reaction mechanism.
- phosphate oxyacids and anions It is not always necessary to use a salt of the oxyacid anion which forms the type of monomer structure shown above.
- a salt of the oxyacid anion which forms the type of monomer structure shown above.
- phosphorus although metaphosphate salts are preferred, other oxyacid salts such as orthophosphate, diphosphate, triphosphate, polyphosphate, phosphonate, phosphinate, peroxyphosphate, and hypophosphate salts or their free acids may also be used.
- orthophosphate esters is indeed the metaphosphate monomer
- the reactivity of ortho-, di-, tri- and polyphosphate oxyacids can be explained by the fact that in solution these oxyacids and their anions will be in equilibrium with the metaphosphate species via which the reaction appears to proceed.
- metaphosphate is continuously reacting with the HC and so the equilibrium with the other phosphates will be driven to the metaphosphate side allowing the reaction to continue.
- phosphorus based oxyacids which have been found to be useful in the present invention are hetero-oxyacids such as thiophosphate, halophosphates and phosphonitriiic compounds.
- the cation of the oxyacid salt will be such as to ensure that the salt is soluble in the solvent in which the reaction is carried out.
- the cation may be an alkali or alkaline earth metal such as sodium, potassium or magnesium.
- larger cations such as lanthanum, caesium or less ionic species such as lithium and ammonium may be more appropriate.
- the cation may be chosen because of its catalytic effect on the reaction.
- the counter ion will be chosen so that the salt does not have an inappropriate pK value, particularly bearing in mind the preferred pH operating conditions which will be discussed in more detail below.
- the reaction can be carried out in both aqueous and organic solvents.
- organic solvent it is preferred that it is a highly polar solvent such as dimethyl sulphoxide (DMSO).
- This method of forming the reaction mixture works particularly well if the water in the KC/oxyacid salt solution is initially present in considerable excess (for example, at least 2, 5, 10, 20, 50 or 100 .fold (on a weight basis).
- most of the water is removed, so as to leave, say, less than one part (for example from 0.1 to 30% w/w), based on the starting amount of HC or amine.
- a balance has to be struck between considerations of yield, which favour removal of a large amount of water, and considerations of time and energy expenditure, which favours the converse. The optimal place to draw the balance will doubtless vary with the nature of the reactants and the operator's process conditions.
- the water can be removed by any appropriate physical or chemical method. Examples of suitable physical methods, which are generally preferred, are evaporation, evaporation under reduced pressure and freeze drying. Considerations of energy consumption and time will often dictate the best in any particular circumstances.
- An alternat ⁇ ve method for preparing the reaction mixture is to dissolve the HC or amine and the oxyacid or oxyacid salt in an organic solvent which may also contain water in an amount of up to 30% (w/w) based on the starting amount of HC or amine.
- a polar solvent such as dimethylsulphoxide should generally be used. It has been found that in many cases the process is more efficient if the reaction mixture contains water in an amount of from 0.1 to 15% w/w of the HC.
- the reaction can be carried out at almost any pH but a preferred pH range is from 1 to 9 and the best results are obtained when the pH is from 2 to 6.
- a preferred pH range is from 1 to 9 and the best results are obtained when the pH is from 2 to 6.
- one advantage of the reaction is that it does work well under mild conditions of pH, for example from pH 4.5 to 6 and this can be particularly important when the HC or the product ester is sensitive to highly acidic conditions.
- the pH will preferably be greater than 7 in order to ensure that a free amine exists in the reaction mixture.
- the pH will be between 7.5 and 9, although use of pH of 10 or even higher may be necessary in some cases.
- Any hydroxylated compound may be esterified or any amine amidated by this method but, in particular, the method is suitable for the esterification of organic compounds such as: sugars, particularly non-reducing sugars such as trehalose and sucrose and reducing-sugars such as lactose and maltose; proteins; glycoproteins, peptides, giycopeptides and giycoconjugates and other molecules having sugar functionality; amino acids, particularly, serine and threonine; and other organic compounds such as alditols and cyclitols, carboxylic acids, organic oxyacids, particularly phosphates, and compounds containing hydroxyl groups or alkoxy or phenoxy anions.
- organic compounds such as: sugars, particularly non-reducing sugars such as trehalose and sucrose and reducing-sugars such as lactose and maltose; proteins; glycoproteins, peptides, giycopeptides and giy
- the invention has application to polysaccharides other than starch, oligosaccharides (say with 3 to 10 monosaccharide units) and di- and mono-saccharides.
- Inorganic hydroxylated compounds which may be esterified by the method of the invention include oxyacids themselves and, for example, the esterification reaction of the invention is of use for the synthesis of di-, tri- and poly-phosphates.
- reaction is most successful for primary and secondary HCs and amines, although it is possible to esterify tertiary derivatives, particularly if the substituents are not too bulky.
- the reaction mixture After the formation of the starting mixture, it may then be further treated to maximise the esterification reaction. In some cases, it may be preferable to heat the reaction mixture for a time between 0.1 hour and 40 days at a temperature of from 20 to 200°C, preferably 50 to 100°C. The heating may be carried out in a sealed system, particularly if a high temperature is used and will increase the rate of the esterification reaction. Since water is a product of the esterification process, removal of water from the system as the reaction proceeds will cause the equilibrium to be shifted so that more ester is formed from the reaction. One way of removing the water would be to heat the mixture in an unsealed system allowing water to evaporate.
- the ester or amidate products may be isolated by any suitable method: by ion exchange chromatography, for example. If more than one reaction product is obtained, it is generally easy to separate the different products by chromatography. Alternatively, the ester may be left in the resulting mixture and treated or allowed to react further to produce a compound, or mixture, of choice.
- the process of the present invention has made it possible to obtain new esters and amidates which could not be prepared by any previously known route.
- esters of acid-labile sugars such as sucrose and trehalose and therefore, in further aspects of the invention, there are provided trehalose-2-phosphate, trehalose-3-phosphate, trehalose-4-phosphate and a number of mono-orthophosphates of sucrose. These compounds are new and could only have been prepared by previously known methods with considerable difficulty and cost.
- FIGURE 1 is a 1 H nmr spectrum of trehalose-6-phosphate obtained from an orthophosphate salt by the method of the present invention
- FIGURE 2 is a 1 H nmr spectrum of trehalose-2-phosphate obtained from an orthophosphate salt by the method of the present invention
- FIGURE 3 is a 1 H nmr spectrum of trehalose-4-phosphate obtained from an orthophosphate salt by the method of the present invention
- FIGURE 4 is a 1 H nmr spectrum of trehalose-3-phosphate obtained from an orthophosphate salt by the method of the present invention
- FIGURE 5 is a HPLC ion-exchange chromatogram obtained from a sample of ⁇ , ⁇ '-trehalose treated with sodium phosphate according to the method of the present invention.
- FIGURE 6 is a 1 H nmr spectrum of trehalose-3-phosphate obtained from a metaphosphate salt by the method of the present invention.
- FIGURE 7 is a 1 H nmr spectrum of trehalose-6-phosphate obtained from a metaphosphate salt by the method of the present invention.
- Bio-Rad AG 1 The preparation, closed to the atmosphere, is heated at 56 °C for 10 days after which it is reconstituted in deionised water (100 ml) and the solution applied to an anion-exchanged column, 120 ⁇ 2 cm, Bio-Rad AG 1 resin which had been washed successively with 1M sodium hydroxide, water, IM sodium acetate, water and is therefore in the acetate form.
- the expression Bio-Rad AG 1 is a trade mark.
- the column was first washed with water to remove unreacted trehalose (for recycling if so desired) and any other unbound material, and then eluted with a 0.2 to 0.8M ammonium acetate aqueous solution gradient to give fractions containing the isomeric trehalose mono-orthophosphates separated from inorganic orthophosphate.
- the fractions containing the trehalose phosphates were then analysed on an analytical ion-exchange column (Dionex BioLC PA 100) and the fractions containing each of the four pure isomers were combined and their solutions freeze-dried to give as analytically pure amorphous solids, trehalose monophosphates as their ammonium salts.
- Dionex BioLC PA 100 is a trade mark. Fraction 1, 0.085 g (6.6%), fraction 2, 0.035g (2.7%), fraction 3, 0.041g (3.1%), fraction 4, 0.027% (2.1%). Total 0.188g (14.6%). All four products gave, on treatment with the enzyme alkaline phosphates, ⁇ , ⁇ '-trehalose (identified by HPLC ion-exchange chromatography) and inorganic orthophosphate (identified colorimetrically using ammonium molybdate).
- Example 2 Using conditions similar to those of Example 1, but modified as shown in the six entries (a) to (f) for Example 2 in Table 1, phosphate esters of ⁇ , ⁇ '-trehalose were prepared from ⁇ , ⁇ '-trehalose.
- sucrose is an extremely acid labile disaccharide and consequently is not amenable to direct phosphorylation with phosphoric acid.
- sucrose is an extremely acid labile disaccharide and consequently is not amenable to direct phosphorylation with phosphoric acid.
- the majority of the sucrose isomeric esters are new compounds and, furthermore, would be very difficult to creoare using existing methods. Examples 4 to 7
- esterification method of the invention is extremely flexible and can be used to esterify a large range of compounds under relatively mild conditions.
- the starting materials can be recycled so that increased amounts of product can be obtained.
- Example 8 Formation of phosphate esters from preparations of ⁇ , ⁇ ' -trehalose and sodium metaphosphate.
- Example 2 The procedure of Example 1 was repeated except that ⁇ , ⁇ '-trehalose dihydrate (1.0 g, 2.6 mmol) was dissolved in a solution of sodium metaphosphate (0.1 M, 100 mi). The preparation is frozen to -78° as before, freeze dried, closed to the atmosphere and heated at 56°C for either 5 days or 12 days. The reaction was repeated at different PH values and the results are shown in Table 2 below.
- the percentage of phosphate shown in Table 2 is determined from detector response and is therefore an underestimate, possibly by a factor as high as 2.
- the amount of phosphate formed will depend upon the moisture content and on the temperature at which the reaction is carried cut. In several separate experiments carried cut at higher temperature but for shorter times, the yield of phosphates increased to about 40% based on detector response. Again, this is an underestimate and the true value may be as much as twice the detector response value.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biochemistry (AREA)
- Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Genetics & Genomics (AREA)
- Saccharide Compounds (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP93917889A EP0652886A1 (en) | 1992-07-28 | 1993-07-22 | Esterification process |
AU47147/93A AU4714793A (en) | 1992-07-28 | 1993-07-22 | Esterification process |
JP6504297A JPH07509457A (en) | 1992-07-28 | 1993-07-22 | Esterification method |
FI950381A FI950381A (en) | 1992-07-28 | 1995-01-27 | Procedure for esterification |
NO950321A NO950321D0 (en) | 1992-07-28 | 1995-01-27 | Esterification Process |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9216026.6 | 1992-07-28 | ||
GB929216026A GB9216026D0 (en) | 1992-07-28 | 1992-07-28 | Esterification process |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1994002495A1 true WO1994002495A1 (en) | 1994-02-03 |
Family
ID=10719437
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/GB1993/001545 WO1994002495A1 (en) | 1992-07-28 | 1993-07-22 | Esterification process |
Country Status (9)
Country | Link |
---|---|
EP (1) | EP0652886A1 (en) |
JP (1) | JPH07509457A (en) |
AU (1) | AU4714793A (en) |
CA (1) | CA2141301A1 (en) |
FI (1) | FI950381A (en) |
GB (1) | GB9216026D0 (en) |
NO (1) | NO950321D0 (en) |
WO (1) | WO1994002495A1 (en) |
ZA (1) | ZA935408B (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2865762A (en) * | 1954-09-16 | 1958-12-23 | Int Minerals & Chem Corp | Pudding mix |
US2884412A (en) * | 1953-09-04 | 1959-04-28 | Int Minerals & Chem Corp | Phosphate-modified starches and preparation |
US2884413A (en) * | 1956-04-06 | 1959-04-28 | Corn Products Co | Orthophosphate esters of starch |
US2961440A (en) * | 1956-01-23 | 1960-11-22 | Corn Products Co | Process for preparing inorganic starch esters |
EP0228612A2 (en) * | 1985-12-16 | 1987-07-15 | Ss Pharmaceutical Co., Ltd. | A derivative of alpha, alpha-trehalose and a process for preparing the same |
-
1992
- 1992-07-28 GB GB929216026A patent/GB9216026D0/en active Pending
-
1993
- 1993-07-22 JP JP6504297A patent/JPH07509457A/en active Pending
- 1993-07-22 WO PCT/GB1993/001545 patent/WO1994002495A1/en not_active Application Discontinuation
- 1993-07-22 EP EP93917889A patent/EP0652886A1/en not_active Withdrawn
- 1993-07-22 AU AU47147/93A patent/AU4714793A/en not_active Abandoned
- 1993-07-22 CA CA002141301A patent/CA2141301A1/en not_active Abandoned
- 1993-07-27 ZA ZA935408A patent/ZA935408B/en unknown
-
1995
- 1995-01-27 FI FI950381A patent/FI950381A/en not_active Application Discontinuation
- 1995-01-27 NO NO950321A patent/NO950321D0/en unknown
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US2884412A (en) * | 1953-09-04 | 1959-04-28 | Int Minerals & Chem Corp | Phosphate-modified starches and preparation |
US2865762A (en) * | 1954-09-16 | 1958-12-23 | Int Minerals & Chem Corp | Pudding mix |
US2961440A (en) * | 1956-01-23 | 1960-11-22 | Corn Products Co | Process for preparing inorganic starch esters |
US2884413A (en) * | 1956-04-06 | 1959-04-28 | Corn Products Co | Orthophosphate esters of starch |
EP0228612A2 (en) * | 1985-12-16 | 1987-07-15 | Ss Pharmaceutical Co., Ltd. | A derivative of alpha, alpha-trehalose and a process for preparing the same |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6146886A (en) * | 1994-08-19 | 2000-11-14 | Ribozyme Pharmaceuticals, Inc. | RNA polymerase III-based expression of therapeutic RNAs |
US6852535B1 (en) | 1994-08-19 | 2005-02-08 | Sirna Therapeutics, Inc. | Polymerase III-based expression of therapeutic RNAS |
Also Published As
Publication number | Publication date |
---|---|
ZA935408B (en) | 1995-01-27 |
FI950381A0 (en) | 1995-01-27 |
GB9216026D0 (en) | 1992-09-09 |
EP0652886A1 (en) | 1995-05-17 |
AU4714793A (en) | 1994-02-14 |
FI950381A (en) | 1995-01-27 |
JPH07509457A (en) | 1995-10-19 |
CA2141301A1 (en) | 1994-02-03 |
NO950321L (en) | 1995-01-27 |
NO950321D0 (en) | 1995-01-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Khorana | Carbodiimides. Part V. 1 A Novel Synthesis of Adenosine Di-and Triphosphate and P1, P2-Diadenosine-5'-pyrophosphate | |
Turner et al. | Studies on Polynucleotides. VI. 1 Experiments on the Chemical Polymerization of Mononucleotides. Oligonucleotides Derived from Thymidine-3'Phosphate2 | |
Moffatt et al. | Nucleoside Polyphosphates. VIII. 1 New and Improved Syntheses of Uridine Diphosphate Glucose and Flavin Adenine Dinucleotide Using Nucleoside-5'Phosphoramidates2 | |
Tener | 2-Cyanoethyl Phosphate and its Use in the Synthesis of Phosphate Esters1 | |
Tener et al. | Studies on Polynucleotides. II. 1 The Synthesis and Characterization of Linear and Cyclic Thymidine Oligonucleotides2 | |
Takanami | Analysis of the 5′-terminal nucleotide sequences of ribonucleic acids: I. The 5′-termini of Escherichia coli ribosomal RNA | |
Saffhill | Selective phosphorylation of the cis-2', 3'-diol of unprotected ribonucleosides with trimetaphosphate in aqueous solution | |
Ralph et al. | Studies on Polynucleotides. XVIII. 1 Experiments on the Polymerization of Mononucleotides. The Synthesis and Characterization of Deoxyguanosine Oligonucleotides 2 | |
Jenny et al. | Synthesis and physical characterization of bis 3′→ 5′ cyclic dinucleotides (NpNp): RNA polymerase inhibitors | |
Cook et al. | Nucleoside S-alkyl phosphorothioates. II. Preparation and chemical and enzymic properties | |
LE DUR et al. | Novel Type of Endotoxin Structure Present in Bordetella pertussis: Isolation of Two Different Polysaccharides Bound to Lipid A | |
Smith et al. | [94] Preparation of nucleotides and derivatives | |
Faust et al. | Synthesis of a Protein‐Reactive ATP Analog and Its Application for the Affinity Labeling of Rabbit‐Muscle Actin | |
SAWAI et al. | Synthesis of 2'-5'linked Oligouridylates in aqueous medium using the Pd2+ Ion | |
US3709873A (en) | Process for synthesizing the di-esters of condensed phosphoric acid | |
Chambers et al. | Nucleoside Polyphosphates. V. 1 Syntheses of Guanosine 5'-Di-and Triphosphates | |
WO1994002495A1 (en) | Esterification process | |
Khorana et al. | Nucleoside Polyphosphates. IX. 1 The Reversible Formation of Pyrophosphates from Monoesters of Phosphoric Acid by Reaction with Acetic Anhydride2 | |
US2970139A (en) | 5-fluorouracil nucleotides and preparation thereof | |
Baron et al. | Nucleotides. Part XXXIII. The structure of cytidylic acids a and b | |
OHTSUKA et al. | Studies on Transfer Ribonucleic Acids and Related Compounds. XXI.: Synthesis and Properties of Guanine Rich Fragments from E. coli tRNAMetf 5'-End | |
Ibanez et al. | Condensation of mononucleotides by imidazole | |
Burton et al. | On the possible role of crystals in the origins of life: VII. The Adsorption and Polymerization of Phosphoramidates by Montmorillonite Clay | |
Potter et al. | A stereospeifically 18 O-labelled deoxydinucleoside phosphate block for incorporation into an oligonucleotide | |
US2795580A (en) | Synthesis of nucleoside polyphosphates |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AT AU BB BG BR BY CA CH CZ DE DK ES FI GB HU JP KP KR KZ LK LU MG MN MW NL NO NZ PL PT RO RU SD SE SK UA US VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 1993917889 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2141301 Country of ref document: CA Ref document number: 254856 Country of ref document: NZ Ref document number: 950381 Country of ref document: FI |
|
WWP | Wipo information: published in national office |
Ref document number: 1993917889 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1993917889 Country of ref document: EP |